Discussing the Safety Profile of Cabazitaxel in mCRPC

October 20, 2019
Arash Rezazadeh Kalebasty, MD

Arash Rezazadeh Kalebasty, MD, a hematologist/oncologist and research program director, Urologic Oncology, Norton Cancer Institute, discusses the safety profile of cabazitaxel in the CARD trial, which randomized patients with metastatic castration-resistant prostate cancer to cabazitaxel or one of 2 antiandrogen receptor agents, abiraterone acetate or enzalutamide.

Arash Rezazadeh Kalebasty, MD, a hematologist/oncologist and research program director, Urologic Oncology, Norton Cancer Institute, discusses the safety profile of cabazitaxel (Jevtana) in the CARD trial, which randomized patients with metastatic castration-resistant prostate cancer (mCRPC) to cabazitaxel or one of 2 antiandrogen receptor agents, abiraterone acetate (Zytiga) or enzalutamide (Xtandi).

Patients who received cabazitaxel did experience some grade 3 or higher toxicities, but those toxicities were not much higher than those experienced in the antiandrogen arm, Kalebasty says. He also notes that these safety results are promising because safety is particularly important when treating patients with mCRPC because these patients are more likely to be elderly.